Amneal Lines Up Ready-To-Use Pemetrexed Hybrid

Q1 2024 Launch Planned After FDA Approval For Pemrydi 505(b)(2) Oncology Injectable

 
• By David Wallace
Amneal
The FDA has approved Amneal’s Pemrydi RTU

More from Products

More from Generics Bulletin